today
treatment
bacteri
infect
major
challeng
due
grow
rate
multidrugresist
bacteria
complic
treatment
increas
healthcar
cost
moreov
new
treatment
bacteri
infect
limit
oligonucleotid
aptam
singl
strand
dna
rna
targetselect
highaffin
featur
consid
nucleic
acidbas
affin
ligand
replac
monoclon
antibodi
aptamerbas
system
found
talent
tool
treatment
microbi
infect
regard
promis
antibiofilm
antimicrobi
activ
reduc
inhibit
effect
bacteri
toxin
inhibit
pathogen
invas
immun
cell
well
use
drug
deliveri
system
focu
review
therapeut
applic
aptam
infect
regard
introduct
infect
relat
challeng
present
first
aptam
definit
select
brief
histori
aptam
develop
variou
pathogen
toxin
review
divers
strategi
aptam
applic
drug
deliveri
well
effect
aptam
immun
system
main
natur
agent
human
defens
pathogen
also
discuss
final
futur
trend
clinic
applic
technolog
discuss
despit
signific
advanc
prevent
treatment
infecti
diseas
expand
daytoday
howev
infect
still
one
lead
caus
death
worldwid
past
year
number
approv
antibacteri
drug
new
mechan
action
becom
declin
incorrect
use
antibiot
lead
side
effect
importantli
develop
bacteri
drug
resist
due
increas
incid
antibioticresist
bacteri
strain
antibiot
select
infect
control
restrict
antibioticresist
bacteria
caus
numer
death
everi
year
direct
impact
economi
moreov
biofilmform
bacteria
result
chronic
infect
develop
increas
resist
antibiot
treatment
host
defens
system
therefor
new
strategi
infect
control
develop
novel
antibiot
less
seriou
side
effect
low
toxic
high
efficaci
seem
necessari
small
singlestrand
dna
rna
bind
specif
target
high
affin
select
call
aptam
produc
method
name
systemat
evolut
ligand
exponenti
enrich
selex
modifi
selex
strategi
divers
analyt
clinic
applic
diagnosi
treatment
aptam
also
evalu
antimicrobi
agent
today
aptam
consid
rang
clinic
evalu
wide
rang
human
disord
power
flexibl
tool
therapeut
goal
review
focus
role
aptam
treatment
microbi
infect
complex
immunogen
addit
higher
affin
specif
varieti
target
protein
cell
small
molecul
well
flexibl
therefor
attach
interior
nonaccess
epitop
easili
target
antibodi
also
show
stabil
addit
fact
denatur
return
proper
primari
conform
without
loss
activ
sever
import
attribut
aptam
make
promis
altern
antibodi
includ
thermal
chemic
stabil
simpl
chemic
synthesi
reduc
cost
product
time
possibl
made
modif
chemic
synthesi
process
make
adapt
differ
applic
sirna
fluorophor
radioisotop
electrochem
system
well
variou
nanoparticl
coupl
aptam
addit
aptam
block
function
target
protein
result
promis
candid
develop
new
therapeut
infect
aptam
appli
divers
valuabl
field
life
scienc
exampl
develop
new
drug
diagnost
bioimag
agent
drug
deliveri
agent
analyt
reagent
food
inspect
hazard
detect
addit
aptam
function
divers
includ
abil
block
interact
receptorligand
activ
function
target
receptor
well
also
act
promis
target
carrier
select
deliv
therapeut
agent
target
cell
howev
sever
disadvantag
also
report
aptam
sensit
enzymat
degrad
nucleas
cell
blood
circul
correspondingli
challeng
regard
topic
system
administr
drug
low
molecular
weight
short
time
aptam
resid
circul
emerg
signific
challeng
regard
renal
filtrat
control
drawback
overcom
appropri
strategi
exampl
aptam
formul
larg
moieti
increas
molecular
weight
reduc
renal
filtrat
chemic
modif
ad
specif
function
group
order
improv
aptam
lifetim
stabil
bodi
occur
primarili
selex
protocol
postselex
modif
one
challeng
resolv
strategi
conjug
aptam
nanomateri
decreas
variou
challeng
ahead
aptam
produc
vitro
procedur
specif
isol
aptam
target
interest
involv
repetit
selectionamplif
round
term
selex
main
advantag
procedur
select
aptam
nucleic
acidbas
affin
ligand
without
prior
knowledg
target
one
modifi
selex
procedur
cellselex
use
discov
specif
aptam
whole
cell
fig
word
cell
consid
target
select
process
oligonucleotid
librari
consist
distinct
sequenc
random
region
librari
usual
base
long
flank
constant
primer
sequenc
end
facilit
pcr
amplif
separ
targetbound
sequenc
unbound
one
via
affinitybas
partit
method
amplif
bound
sequenc
pcr
import
phase
selex
method
amplifi
sequenc
convert
singl
strand
form
singl
strand
oligonucleotid
enter
next
cycl
selex
previou
round
select
cycl
repeat
sever
time
achiev
highaffin
sequenc
enrich
pool
ident
dna
pool
individu
determin
clone
sequenc
next
gener
sequenc
techniqu
sever
neg
select
cycl
develop
selex
process
reduc
nonspecif
bound
oligonucleotid
enhanc
specif
evolv
pool
type
selex
extens
appli
develop
aptam
bacteria
pathogen
cell
low
divers
dna
librari
sequenc
pcr
reagent
contamin
contamin
elut
sequenc
target
cell
strong
nonspecif
bind
low
frequenc
target
molecul
cell
chang
cellular
state
affect
neg
enrich
aptam
sequenc
antimicrobi
activ
aptam
report
number
studi
aptam
target
bacteri
infect
list
tabl
sever
import
exampl
discuss
follow
paragraph
multidrugresist
mdr
strain
bacteria
salmonella
develop
due
inappropri
use
antibiot
accordingli
novel
antimicrobi
agent
requir
fight
resist
strain
report
effect
aptam
coloni
format
typhimurium
enteritidi
studi
indic
min
incub
specif
aptam
bacteria
could
result
signific
growth
inhibit
antimicrobi
effect
aptam
might
result
bacteri
cell
wall
depolar
mycobacterium
tuberculosi
mtb
bacterium
caus
tuberculosi
anoth
import
human
pathogen
develop
variou
mechan
multipli
surviv
resistantli
lung
confus
immun
system
polyphosph
kinas
ppk
gene
mtb
regul
intracellular
metabol
inorgan
polyphosph
polyp
play
main
role
bacteri
persist
inhibit
ppk
activ
result
interfer
polypdepend
process
aptam
therapeut
agent
develop
mtb
concentr
could
complet
inhibit
protein
bacteria
process
exhibit
promis
antimicrobi
activ
mtb
biofilm
persist
commun
microb
embed
matrix
exopolysaccharid
adher
surfac
biofilm
import
human
infect
hard
treat
easili
erad
current
antibiot
chronic
infect
biofilmform
strain
associ
accumul
bacteria
much
complex
antibiot
resist
profil
due
failur
antibiot
penetr
polysaccharid
layer
well
biofilm
resista
human
immun
system
treatment
biofilm
infect
current
seriou
problem
antibiot
therapi
alon
often
inadequ
complet
treatment
biofilm
shown
microbi
infect
motil
initi
attach
believ
major
featur
biofilm
format
found
bind
specif
aptam
flagella
salmonella
choleraesui
could
result
restrict
bacteri
rotat
frequenc
due
increment
electrostat
repuls
cell
surfac
therefor
prevent
format
matur
biofilm
fig
addit
shown
presenc
aptam
cell
easili
attack
antibiot
studi
indic
pretreat
biofilm
form
choleraesui
aptam
concentr
could
substanti
decreas
amount
ampicillin
need
similar
inhibit
well
prevent
develop
antibiot
resist
strain
could
conclud
use
aptam
pretreat
could
elimin
need
highli
potent
antibiot
high
dose
streptococcu
pneumonia
anoth
fundament
pathogen
involv
major
bacteri
pneumonia
major
caus
mening
septicemia
otiti
media
sinus
wildtyp
strain
abl
form
biofilm
state
invas
lung
brain
among
known
dna
aptam
pneumonia
aptam
report
effect
prevent
therapi
antibiofilm
activ
combin
therapi
appropri
antibiot
could
prevent
bacteri
colon
aptam
concentr
could
reduc
biofilm
format
result
studi
suggest
specif
aptam
novel
antibiofilm
agent
help
combat
increas
rate
antibiot
resist
therefor
aptam
offer
tremend
opportun
effect
treatment
chronic
infect
also
serv
better
erad
biofilm
format
bacteria
gener
use
aptam
antibiofilm
activ
lessen
dose
durat
antibiot
therapi
chronic
resist
infect
thu
reduc
risk
abus
misus
antibiot
administr
toxin
power
bioactiv
molecul
produc
variou
bacteri
pathogen
play
key
role
pathogenesi
bacteria
essenti
virul
factor
allow
organ
harm
host
variou
physiopatholog
pathway
toxin
may
target
macrophag
neutrophil
result
reduct
intrins
immun
respons
result
provid
suitabl
environ
activ
bacteri
prolifer
bacteri
toxin
may
degrad
signal
pathway
disrupt
structur
host
cell
lead
persist
infect
aptam
demonstr
power
inhibitori
agent
bacteri
toxin
fig
staphylococcu
aureu
import
human
pathogen
among
staphylococci
virul
toxin
far
although
organ
frequent
part
normal
human
microflora
caus
import
opportunist
infect
suitabl
condit
aureu
may
caus
wide
rang
infect
quickli
becom
resist
mani
antibiot
one
key
virul
factor
aureu
alpha
toxin
form
heptamer
pore
target
cell
membran
caus
tissu
damag
overexpress
show
major
role
destruct
epitheli
cell
cell
death
caus
aureu
alphatoxin
four
aptam
develop
specif
prevent
alpha
toxininduc
cytolysi
activ
viabil
cell
presenc
toxin
treatment
four
aptam
increas
moreov
enterotoxin
b
seb
aureu
caus
staphylococc
toxic
shock
syndrom
tss
rare
observ
enterotoxin
type
seb
one
virul
agent
aureu
act
superantigen
stimul
cell
produc
storm
cytokin
manifest
clinic
complic
food
poison
report
aptam
prevent
sebmedi
express
inflammatori
cytokin
gene
mediat
septic
shock
could
significantli
inhibit
seb
activ
onset
toxic
cascad
prior
patholog
activ
cell
anoth
exampl
aptam
could
bind
staphylococc
enterotoxin
sea
main
compon
aureu
pathogenesi
effect
neutral
sea
well
significantli
decreas
cytokin
secret
blockag
toxic
cascad
caus
sea
may
effect
approach
treatment
searel
ill
bacillu
anthraci
anoth
import
pathogen
genu
bacillu
caus
emerg
anthrax
virul
b
anthraci
depend
product
anthrax
toxin
anthrax
toxin
consist
three
compon
one
protect
antigen
pa
activ
pa
heptam
bind
one
fig
schemat
present
aptam
function
differ
microbi
toxin
bind
oligomer
way
creat
pore
toxin
heptam
insert
target
cell
lead
cell
lysi
presenc
aptam
bind
oligomer
pore
format
occur
inhibit
cell
lysi
b
apc
antigen
present
cell
se
staphylococc
enterotoxin
se
bound
mhc
class
ii
tcr
express
cd
cell
mhc
class
ii
se
tcr
interact
may
result
hyper
activ
cell
lead
excess
prolifer
cell
uncontrol
burst
numer
pro
inflammatori
cytokin
chemokin
aptam
inhibit
tcell
activ
therefor
product
cytokin
occur
c
pa
protect
antigen
bind
anthrax
toxin
receptor
interact
lf
form
lethal
toxin
transloc
lf
pa
heptam
channel
host
cell
cytosol
result
cell
death
aptam
block
activ
site
lf
lead
cell
surviv
bont
botulinum
intern
endosom
cytosol
proteolysi
light
chain
cleavag
snare
protein
synaptobrevin
syntaxin
neuron
prevent
releas
acetylcholin
aptam
bound
light
chain
toxin
caus
strong
inhibit
endopeptidas
activ
molecul
edema
factor
ef
lethal
factor
lf
facilit
pass
complex
cell
ef
pa
form
edema
toxin
main
virul
factor
b
anthraci
lf
zinc
metalloproteas
activ
capabl
cleav
kinas
enzym
known
mitogenactiv
protein
kinas
mek
famili
block
interact
lf
lead
reduct
lf
toxic
ssdna
aptam
report
could
bind
strongli
impress
inhibitor
lf
block
activ
site
lf
prevent
proteas
activ
serv
promis
drug
candid
neutral
lf
toxic
anoth
import
toxin
relat
syndrom
botul
caus
clostridium
botulinum
botulinum
neurotoxin
bont
one
lethal
toxin
human
also
consid
biolog
weapon
type
b
e
main
caus
human
ill
type
strongest
one
among
serotyp
toxin
kda
protein
cleav
kda
kda
protein
link
disulfid
bond
light
chain
lc
zincendopeptidas
activ
nontox
subunit
heavi
chain
carboxyltermin
botulinum
heavi
chain
bind
target
nerv
cell
stimul
endocytosi
toxin
molecul
lc
inactiv
protein
regul
releas
acetylcholin
result
block
neurotransmiss
peripher
cholinerg
synaps
three
aptam
bont
report
bound
lc
inhibit
constant
low
nm
rang
could
caus
strong
inhibit
endopeptidas
activ
convent
therapi
antibiot
face
seriou
restrict
includ
low
intracellular
drug
concentr
loss
drug
efflux
pump
enzymat
degrad
develop
multidrug
resist
mdr
strain
drug
deliveri
system
introduc
numer
profit
includ
improv
treatment
increas
efficaci
durat
drug
activ
increas
patient
satisfact
reduc
requir
dose
drug
adapt
conveni
rout
administr
deliv
target
site
reduc
unwant
effect
reduct
cost
treatment
gener
due
good
stabil
expand
load
capac
improv
physicochem
featur
aptam
bind
specif
cell
surfac
receptor
molecul
therefor
aptamerbas
deliveri
system
improv
cellular
entranc
therapeut
agent
aptam
design
wide
rang
applic
coupl
nanoparticl
drug
nucleic
acid
nano
carrier
drug
carrier
play
major
role
cell
intern
fig
np
small
particl
size
nm
exhibit
potenti
antimicrobi
activ
thu
appropri
suit
fight
microbi
infect
antibiot
encapsul
np
larg
capac
replac
antibiot
free
form
numer
benefit
nanoencapsul
strategi
verysmal
size
big
surfacezonetomass
ratio
high
load
capac
high
reactiv
protect
antibiot
physic
inactiv
improv
antibiot
pharmacokinet
facilit
antibiot
releas
infect
area
reduc
requir
dose
drug
assembl
aptamersnanoparticl
result
increas
target
effici
therapeut
np
possess
accept
biocompat
defend
nucleic
acid
destruct
caus
nucleas
digest
regard
aptam
conjug
np
promis
tool
drug
deliveri
antimicrobi
peptid
amp
consid
suitabl
drug
candid
treat
mdr
bacteria
unstabl
vivo
short
halflif
low
penetr
mammalian
cell
antimicrobi
peptid
load
onto
gold
nanoparticl
conjug
vibrio
vulnificu
specif
dna
aptam
result
composit
promot
bacteri
degrad
destroy
integr
v
vulnificu
membran
thu
caus
bacteri
cell
death
studi
follow
intraven
inject
aunpapt
induc
mortal
infect
mice
compar
alon
mortal
aunpapt
exhibit
bactericid
activ
concentr
nm
aunpapt
sever
advantag
aunpapthi
enabl
effici
intracellular
deliveri
host
increas
stabil
protect
proteolysi
help
avoid
shortterm
reiter
administr
reduc
overal
cost
therapi
system
simpl
show
evid
host
toxic
similar
note
yeom
jh
et
al
report
ctermin
hexahistidinetag
amp
load
onto
aunp
conjug
histag
dna
aptam
aunpapt
order
success
effect
deliv
antimicrobi
peptid
salmonellainfect
hela
cell
antihistag
aptam
improv
attach
histagamp
np
system
design
improv
amp
stabil
intracellular
deliveri
potenti
impact
elimin
intracellular
salmonella
typhimurium
infect
disrupt
bacteri
cell
vivo
evalu
system
mice
also
indic
promis
result
effect
aptamerconjug
nanoparticl
biofilm
format
also
evalu
report
singlewal
carbon
nanotub
swnt
signific
antimicrobi
activ
util
nanomateri
detect
pseudomona
aeruginosa
well
could
increas
toxic
effect
antimicrobi
agent
bacteri
biofilm
specif
aptam
p
aeruginosa
bind
affin
nm
rang
develop
conjug
swnt
could
produc
effect
concentr
particl
around
bacteri
cell
result
disrupt
bacteria
accumul
compar
swnt
alon
swnt
caus
higher
inhibit
biofilm
format
increas
effici
antibiofilm
activ
swnt
anoth
effect
aptamernanoparticl
complex
biofilm
also
report
graphen
oxid
go
extens
use
chemic
modifi
graphen
deriv
antimicrobi
activ
research
group
studi
conjug
four
differ
aptam
sequenc
go
order
appli
antibiofilm
agent
typhimurium
model
aptam
conjug
graphen
oxid
provid
power
platform
imped
biofilm
format
target
manner
show
synergist
effect
aptam
go
biofilm
format
use
effect
antibiofilm
concentr
go
decreas
mgl
mgl
antibiofilm
effect
enhanc
actual
go
entri
biofilm
facilit
aptam
could
reduc
cellular
membran
potenti
inhibit
bacteri
growth
time
result
support
aptam
therapeut
candid
drug
deliveri
aptamersirnamirna
conjug
short
interf
rna
sirna
base
pair
bp
length
exogen
agent
experiment
manipul
gene
express
sirna
compar
similar
therapeut
agent
exhibit
minim
toxic
high
stabil
sirna
demonstr
promis
modulatori
effect
virul
drug
resist
pathogenesi
use
sirnaaptam
conjug
drug
deliveri
result
increas
favor
therapeut
efficaci
safeti
viral
challeng
infect
cell
encod
mirna
capabl
influenc
host
cell
rnai
system
induc
transcript
gene
silenc
tg
viral
genom
thu
form
latenc
viral
infect
addit
present
exogen
sirna
mirna
shrna
infect
cell
target
integr
viral
promot
significantli
repress
viral
transcript
tg
cell
aptam
sirna
conjug
induc
tg
suppress
viral
level
also
reduc
cell
deplet
actual
aptam
function
deliv
sirna
induc
tg
gener
receptordirect
aptam
deliv
small
rna
function
modul
infect
well
viral
transcript
accord
presenc
well
easili
add
function
group
termin
oligonucleotid
sequenc
drug
molecul
easili
bound
aptam
exampl
ampicillin
ineffect
biofilm
format
choleraesui
infect
aptam
ampicillin
conjug
could
produc
synergist
result
biofilm
aptam
antibiot
carrier
help
ampicillin
penetr
biofilm
kill
bacteria
reduc
biofilm
toler
drug
tetracyclineload
hydrogel
consid
control
releas
use
dna
oligonucleotid
aptam
similar
agent
increas
tetracyclin
load
sustain
releas
studi
design
base
physicochem
featur
nucleic
acid
sequenc
possibl
interact
oligonucleotid
tetracyclin
oligonucleotid
could
rise
partit
coeffici
tetracyclin
hydrogel
drug
load
solut
also
could
slow
releas
tetracyclin
hydrogel
increas
bacteri
inhibit
pdt
noninvas
techniqu
includ
three
item
visibl
light
photosensit
ps
oxygen
approv
antimicrobi
therapi
treatment
infect
studi
discuss
applic
aptamerconjug
ps
indic
complex
could
increas
select
pdt
phototherm
therapi
ptt
belong
group
phototherapi
produc
reactiv
oxygen
speci
therebi
induc
oxid
stress
slightli
invas
low
toxic
nearbi
healthi
tissu
photon
energi
convert
heat
methicillin
resist
aureu
mrsa
famou
pathogen
produc
seriou
infect
resist
mani
common
antibiot
order
increas
mrsa
treatment
effici
aptamerfunction
gold
nanorod
apt
au
nr
introduc
target
ptt
specif
bound
mrsa
cell
result
recognit
inactiv
mrsa
cell
hyperthermia
immobil
aptam
surfac
aunr
led
increas
target
mrsa
cellbind
affin
light
strongli
absorb
gold
nanoparticl
caus
quick
convers
photon
energi
heat
bacteri
specif
aptam
promis
agent
prevent
pathogen
invas
immun
cell
fig
exampl
illustr
follow
section
infecti
pathogen
invad
host
immun
cell
made
treatment
complex
exampl
past
year
almost
billion
death
caus
mtb
intracellular
bacterium
surviv
multipli
within
macrophag
macrophag
kill
bacilli
make
harder
control
infect
mtbhiv
coinfect
case
appear
multipl
drug
resist
strain
activ
macrophag
mtb
begin
multipli
within
cell
macrophag
develop
enhanc
abil
kill
bacilli
infect
cell
sinc
invas
macrophag
major
step
mtb
infect
process
specif
aptam
virul
marker
mtb
prevent
invas
immun
cell
aptam
mtb
specif
dna
aptam
kd
nm
rang
consider
inhibit
virul
mtb
invas
macrophag
vitro
virul
mtb
affect
aptam
could
stimul
secret
macrophag
led
enhanc
macrophag
function
mtb
increas
surviv
mtb
infect
mice
decreas
develop
activ
mtb
respect
salmonella
enterica
serovar
typhi
typhi
produc
feverish
diseas
call
typhoid
fever
ivb
pili
express
typhi
main
charact
develop
epidem
typhoid
fever
monocyt
macrophag
critic
effector
molecul
play
crucial
role
defens
salmonella
bacteri
infect
sever
aptam
recent
develop
specif
bind
type
ivb
pili
interfer
bacteri
pathogenesi
inhibit
bacteri
aggreg
inhibit
entri
bacteria
human
monocyt
cell
studi
rna
aptam
gener
base
selex
procedur
one
exhibit
bind
affin
nm
rang
typhi
type
ivb
pili
viral
infect
threat
human
health
effect
earli
treatment
improv
prognosi
diseas
due
repeat
viru
mutat
virus
escap
immun
system
mani
viral
drug
ineffect
addit
mani
antivir
drug
caus
sever
side
effect
may
interfer
drug
agent
lead
low
efficaci
target
treatment
aptam
appli
varieti
virus
effect
antivir
therapi
sever
method
suppress
viral
nucleic
acid
replic
inhibit
nucleocapsid
assembl
reduc
extracellular
dna
hepat
b
viru
hbv
exhibit
featur
aptam
imped
viru
bind
host
cell
exampl
influenza
viru
hemagglutinin
bind
sialic
acid
receptor
host
cell
play
fundament
role
initi
viral
infect
dna
aptam
obstruct
influenza
viru
infect
block
viru
attach
host
cell
also
aptam
prevent
rabi
viru
enter
host
cell
block
interact
viru
host
cell
receptor
moreov
penetr
process
herp
simplex
viru
gd
protein
major
determin
herp
simplex
hsv
entri
two
aptam
select
interf
interact
gd
protein
target
cell
receptor
fact
variou
enzym
import
viru
replic
cycl
enzym
attract
target
target
antivir
aptam
rna
aptam
select
could
inhibit
enzym
activ
hiv
tat
revers
transcriptas
hepat
c
viru
hcv
proteasehelicas
rnadepend
rna
polymeras
sar
sever
acut
respiratori
syndrom
coronaviru
scv
ntpase
helicas
aptam
develop
antivir
therapeut
agent
summar
tabl
moreov
aptam
may
applic
drug
develop
one
exampl
regard
rna
aptam
develop
aminoglycosid
vitro
select
discov
interact
aminoglycosid
natur
rna
includ
hiv
rna
may
similar
mechan
interact
vitro
select
aminoglycosid
aptam
seem
valuabl
applic
discoveri
pathogenesi
treatment
hiv
infect
includ
molecular
mechan
interact
aminoglycosid
antibiot
screen
effici
antihiv
drug
candid
parasit
infect
seriou
impact
health
worldwid
mani
drug
use
today
effect
caus
sever
complic
tri
find
novel
agent
control
parasit
infect
great
attent
variou
strategi
develop
parasitespecif
aptam
prevent
interact
parasit
host
trypanosoma
cruzi
parasit
invad
host
cell
ulrich
et
al
identifi
aptam
could
block
receptorligand
interact
cruzi
epitheli
monkey
kidney
host
cell
thu
inhibit
cell
invas
aptam
inhibit
function
protein
erythrocyt
membran
protein
key
factor
pathogen
plasmodium
falciparum
protein
involv
parasit
adhes
erythrocyt
specif
rna
aptam
abl
detect
protein
surfac
infect
erythrocyt
aptam
act
antiroset
drug
aptam
target
protein
distinguish
protein
ssdna
aptam
bind
leishmania
infantum
high
affin
identifi
leishmania
protein
anoth
exampl
inhibit
function
protein
poli
bind
protein
pabp
dna
aptam
appabp
appabp
appabp
abl
bind
pabp
essenti
protein
leishmania
infantum
surviv
appabp
degrad
bind
pabp
poli
featur
may
appli
regul
function
pabp
vivo
critic
parasit
virul
surviv
silenc
could
reduc
parasit
mobil
induc
cell
death
rna
aptam
contain
guug
motif
isol
inhibit
entamoeba
histolytica
growth
block
sever
aptam
develop
parasit
infect
summar
tabl
despit
signific
advanc
treatment
infecti
diseas
past
half
centuri
still
mani
problem
associ
develop
effect
therapi
overcom
side
effect
antibiot
pathogen
drug
resist
aptam
could
provid
strong
tool
expans
new
therapeut
factor
abil
block
function
pathogen
microorgan
also
simpl
cheap
therapeut
agent
less
side
effect
compar
tradit
antibiot
differ
therapeut
approach
aptam
applic
report
field
microbi
infect
exampl
aptam
could
inhibit
biofilm
format
inhibit
function
microbi
toxin
therefor
could
use
new
therapeut
tool
combat
chronic
infect
addit
aptam
could
conjug
nanoparticl
sirnamirna
therapeut
drug
pdt
agent
formul
new
therapeut
composit
specif
kill
bacteri
cell
applic
aptam
technolog
treatment
microbi
infect
still
l
infantum
dna
rlipabp
affect
physiolog
role
pabp
p
falciparum
rna
disrupt
sequestr
parasit
reduc
rosett
format
cruzi
rna
cell
adhes
inhibit
cell
invas
brucei
rna
vsg
protein
direct
antibodi
surfac
parasit
rlipabp
recombin
protein
erythrocyt
membran
protein
vsg
variant
surfac
glycoprotein
primal
phase
variou
challeng
need
overcom
review
provid
recent
develop
aptamerbas
technolog
microbi
infect
illustr
promis
technolog
actual
altern
tradit
approach
infect
therapi
aptam
applic
tool
detect
defens
unknown
pathogen
bacteri
fungal
viral
agent
becom
valuabl
antiinfect
therapeut
tool
clinician
recent
futur
